Browse Studies — Arctuva

Phase 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

Estimated

~$10 – $7,500

Institut de Recherches Internationales ServierNCT05786924

Phase 2

Phase 2 Trial of Ulixertinib for Patients With Histiocytic Neoplasms

The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.

Histiocytic Neoplasms

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT06411821

Phase 1

In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undeter…

Non-Hodgkin LymphomaMultiple MyelomaHistiocytic Neoplasms+2 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05093335

International Rare Histiocytic Disorders Registry (IRHDR)

The rare histiocytic disorders (RHDs) are characterized by the infiltration of one or more organs by non-LCH histiocytes. They can range from localized disease…

Rare Histiocytic Disorders (RHDs)Erdheim-Chester Disease (ECD)Rosai-Dorfman Disease (RDD)+7 more

Estimated

~$10 – $750

The Hospital for Sick ChildrenNCT02285582